Literature DB >> 15114660

Coupling of antigen to cholera toxin for dendritic cell vaccination promotes the induction of MHC class I-restricted cytotoxic T cells and the rejection of a cognate antigen-expressing model tumor.

Kristina Eriksson1, Jia-Bin Sun, Inger Nordström, Margareta Fredriksson, Marianne Lindblad, Bin-Ling Li, Jan Holmgren.   

Abstract

We previously demonstrated that cholera toxin (CT) is highly efficient as a combined carrier and adjuvant for dendritic cell (DC) vaccination, inducing strong Th1-dominated B cell and CD4(+) T cell responses. In this study we show that vaccination with DC pre-pulsed ex vivo with CT-conjugated OVA (OVA-CT) gives rise to OVA-specific CD8(+) T cells that produce IFN-gamma and are cytotoxic for OVA-expressing E.G7 tumor cells both in vitro and in vivo. The induction of specific CD8(+) CTL by OVA-CT-treated DC was associated with enhanced presentation of OVA peptide (SIINFEKL) on MHC class I in combination with an overall activation of the pulsed DC. Vaccination of mice with OVA-CT-pulsed DC resulted in rejection of already established MHC class I-positive, MHC class II-negative, OVA-expressing E.G7 tumors in an antigen-specific, CD8(+) T cell-dependent fashion and was associated with high numbers of tumor-infiltrating CD8(+) T cells. Conjugation of antigen to CT facilitated DC uptake of the linked antigen through the GM1 receptor-binding B subunit and induced strong activation-maturation signals through the biologically active A subunit. These results have interesting implications for DC vaccination aimed at inducing CTL immune responses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15114660     DOI: 10.1002/eji.200324368

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  Heteropentameric cholera toxin B subunit chimeric molecules genetically fused to a vaccine antigen induce systemic and mucosal immune responses: a potential new strategy to target recombinant vaccine antigens to mucosal immune systems.

Authors:  Tetsuya Harakuni; Hideki Sugawa; Ai Komesu; Masayuki Tadano; Takeshi Arakawa
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Cholera-toxin suppresses carcinogenesis in a mouse model of inflammation-driven sporadic colon cancer.

Authors:  Michael Doulberis; Katerina Angelopoulou; Eleni Kaldrymidou; Anastasia Tsingotjidou; Zaphiris Abas; Suzan E Erdman; Theofilos Poutahidis
Journal:  Carcinogenesis       Date:  2014-12-30       Impact factor: 4.944

3.  Improved Efficacy of a Dendritic Cell-Based Vaccine against a Murine Model of Colon Cancer: The Helper Protein Effect.

Authors:  Amir-Hassan Zarnani; Monireh Torabi-Rahvar; Mahmood Bozorgmehr; Mehri Zareie; Nazanin Mojtabavi
Journal:  Cancer Res Treat       Date:  2014-11-27       Impact factor: 4.679

4.  The Nontoxic Cholera B Subunit Is a Potent Adjuvant for Intradermal DC-Targeted Vaccination.

Authors:  Laura Antonio-Herrera; Oscar Badillo-Godinez; Oscar Medina-Contreras; Araceli Tepale-Segura; Alberto García-Lozano; Lourdes Gutierrez-Xicotencatl; Gloria Soldevila; Fernando R Esquivel-Guadarrama; Juliana Idoyaga; Laura C Bonifaz
Journal:  Front Immunol       Date:  2018-09-27       Impact factor: 7.561

5.  Construction of Orthogonal Modular Proteinaceous Nanovaccine Delivery Vectors Based on mSA-Biotin Binding.

Authors:  Yixin Shi; Chao Pan; Kangfeng Wang; Yan Liu; Yange Sun; Yan Guo; Peng Sun; Jun Wu; Ying Lu; Li Zhu; Hengliang Wang
Journal:  Nanomaterials (Basel)       Date:  2022-02-22       Impact factor: 5.076

6.  A Short Peptide of Autotransporter Ata Is a Promising Protective Antigen for Vaccination Against Acinetobacter baumannii.

Authors:  Peng Sun; Xin Li; Chao Pan; Zhicheng Liu; Jun Wu; Hengliang Wang; Li Zhu
Journal:  Front Immunol       Date:  2022-04-13       Impact factor: 8.786

Review 7.  Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins.

Authors:  Terry D Connell
Journal:  Expert Rev Vaccines       Date:  2007-10       Impact factor: 5.217

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.